NCT03200249已完成不适用
Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers: Phase 2 Study (RADICAL)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Complete histological response rate
研究概览
简要总结
Hypothesis : Therapeutic intensification by increasing the dose delivered to the tumor by RCMI (conformational radiotherapy by intensity modulation) in order to reduce local relapse, often associated with poor prognosis
Primary objective: evaluate the rate of tumor sterilization and the toxicities of RTCT with concomitant boost in intensity modulation in patients with rectal cancer CT3-T4 and / or cN1-2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adenocarcinoma of the rectum cT3 or cT4 or cN+, M0 and for which CPR recommends preoperative radiochemotherapy
- •Tumor <15 cm of the anal margin in rigid or subperitoneal rectoscopy at the MRI
- •Tumor potentially resectable from the outset, or considered to be resectable after radiochemotherapy
- •Operable Patient
- •Age between 18 and 75
- •OMS performance status 0-2
- •No co-morbidity likely to prevent the delivery of treatment
- •Adequate contraception for men, and for non-menopausal women
- •Neurotrophic neutrophils 1500 / mm3, platelets 100 000 / mm3, and hemoglobin 10 g / dL
- •Bilirubin ≤ 1.5 times the upper limit of normal (LNS), ASAT and ALAT ≤ 1.5LNS, Alkaline phosphatase ≤ 1.5 LNS
- •Creatinine clearance> 50 mL / min
- •Patient must have been informed and must have signed the specific informed consent form.
- •Patient must be affiliated to a Social Health Insurance.
排除标准
- •Remote metastasis
- •Cancer not resectable
- •Contraindication to capecitabine and its excipients
- •Previous history of pelvic radiotherapy or previous chemotherapy
- •History of inflammatory bowel or rectum disease
- •History of angina pectoris monitored or myocardial infarction or heart failure
- •Active active infection or other serious underlying condition that may prevent the patient from receiving treatment
- •Other concomitant cancer, or history of cancer other than in situ cancer of the treated cervix or basal cell carcinoma or squamous cell carcinoma
- •Patient already included in another therapeutic trial with an experimental molecule
- •Pregnant woman, likely to be pregnant or nursing
- •Persons deprived of their liberty or under guardianship
- •Patient unable to comply with the required medical follow-up for geographic, social or psychological reasons
结局指标
主要结局
Complete histological response rate
时间窗: at 8 weeks after inclusion
Absence of residual cancer cells on the final analysis of the tumor and lymph node
次要结局
- Tolerance(at 1, 2, 3, 4, 5 and 13 weeks after inclusion and at 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months after surgery)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
2 期
Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal CancerRectal Cancers.NCT01340508National University Hospital, Singapore63
Unknown
2 期
IMRT-SIB and Capecitabine in Preoperative Rectal Cancer TreatmentRectal CarcinomaNCT02268006Institute of Oncology Ljubljana50
Unknown
2 期
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal CarcinomaChemoradiotherapyNCT00973778Shanghai Jiao Tong University School of Medicine62
招募中
3 期
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04136886Sun Yat-sen University346
招募中
2 期
Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal CancerRectal CancerNCT04801511Zhou Fuxiang60